G

Galderma Group AG
SIX:GALD

Watchlist Manager
Galderma Group AG
SIX:GALD
Watchlist
Price: 86.22 CHF 1.26%
Market Cap: 20.5B CHF
Have any thoughts about
Galderma Group AG?
Write Note

Galderma Group AG
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Galderma Group AG
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
G
Galderma Group AG
SIX:GALD
Operating Income
607.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Transocean Ltd
NYSE:RIG
Operating Income
$173m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-24%
M
MoonLake Immunotherapeutics
NASDAQ:MLTX
Operating Income
-$54.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sealsq Corp
NASDAQ:LAES
Operating Income
-$4.1m
CAGR 3-Years
22%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
TalkPool AG
STO:TALK
Operating Income
€2m
CAGR 3-Years
41%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
R
R&S Group Holding AG
SIX:RSGN
Operating Income
CHf38.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Galderma Group AG
Glance View

Market Cap
20.5B CHF
Industry
N/A

Galderma Group AG is a global leader in dermatology, committed to delivering innovative solutions that enhance the health and beauty of skin. Founded in 1981, the company has cultivated a rich portfolio of products spanning prescription medications and consumer skin health brands. It operates under key brands like Restylane, used for aesthetic solutions, and Cetaphil, known for its gentle skincare products. With a strong emphasis on research and development, Galderma consistently invests in cutting-edge technologies and clinical advancements to meet the diverse needs of its patients and consumers worldwide. As the skin health market continues to expand—driven by increasing awareness of skin conditions and the rise in demand for aesthetic treatments—Galderma is strategically positioned to capture significant growth opportunities. The company's proactive approach to sustainability and focus on patient-centric solutions further solidify its reputation in the industry. For investors, Galderma represents not just a steady performer in the healthcare sector, but also an innovative player navigating the evolving landscape of dermatology. By prioritizing both efficacy and consumer satisfaction, Galderma is not only promoting healthier skin but is also capitalizing on a rapidly growing market—making it a compelling addition to any investment portfolio.

GALD Intrinsic Value
Not Available
G

See Also

What is Galderma Group AG's Operating Income?
Operating Income
607.8m

Based on the financial report for Dec 31, 2023, Galderma Group AG's Operating Income amounts to 607.8m .

What is Galderma Group AG's Operating Income growth rate?
Operating Income CAGR 1Y
52%

Over the last year, the Operating Income growth was 52%.

Back to Top